Verastem Inc (VSTM) Actualités

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge PR...

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Oral presentation of RAMP 201 trial results including updated subgroup analyses in recurrent low-grade serous ovarian cancer Oral presentation...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven...

Form 8-K - Current report

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

New executive leadership supports the company’s transition to a fully integrated commercial-stage organization in a year of transformative growth...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

VS-7375 is a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor currently in Phase 1 development in China in advanced KRAS...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report